DAVITA INC. (DVA)

DaVita Inc. is a leading U.S.-based healthcare provider specializing in kidney care, ranking as one of the two largest dialysis providers in the country. The company delivers comprehensive care across all stages of chronic kidney disease (CKD) through to end stage kidney disease (ESKD), offering services spanning earlier diagnosis, transplant support, home-based care, in-center dialysis, and hospital/skilled nursing facility treatment. Its primary segment, U.S. dialysis, operated 2,724 outpatient dialysis centers across 46 states and the District of Columbia as of December 31, 2022, serving approximately 199,400 patients, and held contracts to provide hospital inpatient dialysis services in roughly 820 hospitals, alongside a specialized ESKD clinical laboratory.

This segment generated approximately 91% of consolidated revenues, sourced primarily from government programs (Medicare, Medicare Advantage, Medicaid) representing about 67% of U.S. dialysis patient service revenues, with commercial insurance comprising the remaining 33% and driving the majority of profitability. DaVita also operates ancillary services including U.S. integrated kidney care (IKC), which provided integrated care and disease management to 42,000 patients in risk-based arrangements and 15,000 patients in other arrangements as of year-end 2022, alongside other ancillary businesses such as clinical research (DaVita Clinical Research), transplant software (MedSleuth), physician practice management services (Nephrology Practice Solutions), and a venture investment group. Internationally, the company served approximately 45,600 patients through 350 outpatient dialysis centers across 11 countries.

The company operates numerous dialysis centers through joint ventures with nephrologists, hospitals, and other healthcare providers, maintaining relationships with over 4,900 referring nephrologists and contracts with over 900 physicians or physician groups for medical director services. DaVita is actively engaged in value-based care models, including CMS's ESRD Treatment Choices (ETC) Model and the Comprehensive Kidney Care Contracting (CKCC) model, aimed at promoting home dialysis, delaying disease progression, and increasing transplant rates. The company has consistently ranked as an industry leader in CMS's Quality Incentive Program and Five-Star Quality Rating system.

In June 2019, DaVita completed the sale of its DaVita Medical Group business to a UnitedHealth Group subsidiary, with that business now reported as discontinued operations. The company continues to navigate ongoing operational and financial impacts from the COVID-19 pandemic, including effects on patient mortality rates, staffing, and regulatory relief measures such as Medicare sequestration adjustments, while also monitoring evolving healthcare policy developments including Medicare Advantage rate changes and potential regulatory shifts affecting noncompete agreements with physicians.